Efficacy of everolimus in second- and third-line therapy for
metastatic renal cell carcinoma: A registry-based analysis

J 2014

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis

BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Kateřina KUBÁČKOVÁ, Igor KISS et. al.

Základní údaje

Originální název

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis

Autoři

BUCHLER, Tomas (703 Slovensko), Zbyněk BORTLÍČEK (203 Česká republika, domácí), Alexandr POPRACH (203 Česká republika), Kateřina KUBÁČKOVÁ (203 Česká republika), Igor KISS (203 Česká republika), Milada ZEMANOVA (203 Česká republika), Ondrej FIALA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, garant, domácí), Rostislav VYZULA (203 Česká republika) a Bohuslav MELICHAR (203 Česká republika)

Vydání

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, New York, ELSEVIER SCIENCE INC. 2014, 1078-1439

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.768

Kód RIV

RIV/00216224:14110/14:00076233

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.urolonc.2013.12.007

UT WoS

000338090800009

Klíčová slova anglicky

Everolimus; mTOR; Renal cell carcinoma; Tyrosine kinase inhibitors; Therapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 11. 2014 08:47, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on everolimus was associated with PFS on previous TKIs in patients receiving 1 but not 2 previous TKIs. Only 13% of 352 patients starting targeted therapy for mRCC in 2010 had received 3 sequential targeted agents by the data cutoff in March 2013. Conclusion: PFS on everolimus correlated with PFS on TKIs in patients pretreated with 1 but not 2 TKIs. Everolimus can be deferred to the third line without loss of efficacy or increased toxicity. However, only a minority of patients with mRCC starting targeted treatment can be expected to receive third-line therapy.

Citovat

BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Kateřina KUBÁČKOVÁ, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Ladislav DUŠEK, Rostislav VYZULA a Bohuslav MELICHAR. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. New York: ELSEVIER SCIENCE INC., 2014, roč. 32, č. 5, s. 569-575. ISSN 1078-1439. Dostupné z: https://dx.doi.org/10.1016/j.urolonc.2013.12.007.

@article{1195775,
   author = {Buchler, Tomas and Bortlíček, Zbyněk and Poprach, Alexandr and Kubáčková, Kateřina and Kiss, Igor and Zemanova, Milada and Fiala, Ondrej and Dušek, Ladislav and Vyzula, Rostislav and Melichar, Bohuslav},
   article_location = {New York},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.urolonc.2013.12.007},
   keywords = {Everolimus; mTOR; Renal cell carcinoma; Tyrosine kinase inhibitors; Therapy},
   language = {eng},
   issn = {1078-1439},
   journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
   title = {Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis},
   volume = {32},
   year = {2014}
}

TY  - JOUR
ID  - 1195775
AU  - Buchler, Tomas - Bortlíček, Zbyněk - Poprach, Alexandr - Kubáčková, Kateřina - Kiss, Igor - Zemanova, Milada - Fiala, Ondrej - Dušek, Ladislav - Vyzula, Rostislav - Melichar, Bohuslav
PY  - 2014
TI  - Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
JF  - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL  - 32
IS  - 5
SP  - 569-575
EP  - 569-575
PB  - ELSEVIER SCIENCE INC.
SN  - 10781439
KW  - Everolimus
KW  - mTOR
KW  - Renal cell carcinoma
KW  - Tyrosine kinase inhibitors
KW  - Therapy
N2  - Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on everolimus was associated with PFS on previous TKIs in patients receiving 1 but not 2 previous TKIs. Only 13% of 352 patients starting targeted therapy for mRCC in 2010 had received 3 sequential targeted agents by the data cutoff in March 2013. Conclusion: PFS on everolimus correlated with PFS on TKIs in patients pretreated with 1 but not 2 TKIs. Everolimus can be deferred to the third line without loss of efficacy or increased toxicity. However, only a minority of patients with mRCC starting targeted treatment can be expected to receive third-line therapy.
ER  -

BUCHLER, Tomas, Zbyněk BORTLÍČEK, Alexandr POPRACH, Kateřina KUBÁČKOVÁ, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Ladislav DUŠEK, Rostislav VYZULA a Bohuslav MELICHAR. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., 2014, roč.~32, č.~5, s.~569-575. ISSN~1078-1439. Dostupné z: https://dx.doi.org/10.1016/j.urolonc.2013.12.007.

Podrobný výpis o publikaci